Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta, Precision Therapeutics Amend Co-marketing Deal Again

NEW YORK (GenomeWeb News) – Rosetta Genomics said after the close of the market on Thursday it and Precision Therapeutics have amended their co-marketing deal entered into in July 2012 and revised in October.

As amended, Rosetta has granted Precision the co-exclusive rights to market Rosetta's Cancer Origin test in the US with Rosetta, it said in a document filed with the US Securities and Exchange Commission. Precision must use "commercially reasonable efforts" to market and promote the test, which was formerly called miRview mets2.

Rosetta will record all revenues for sales of the test and is responsible for sample collection, processing, and billing.

As amended the deal has an initial term of one year and will be automatically renewed for an additional six-month period.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.